[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2024200015A1 - Procédé de production d'un granulat et un granulat, en particulier un composé granulé d'excipients - Google Patents

Procédé de production d'un granulat et un granulat, en particulier un composé granulé d'excipients Download PDF

Info

Publication number
WO2024200015A1
WO2024200015A1 PCT/EP2024/056746 EP2024056746W WO2024200015A1 WO 2024200015 A1 WO2024200015 A1 WO 2024200015A1 EP 2024056746 W EP2024056746 W EP 2024056746W WO 2024200015 A1 WO2024200015 A1 WO 2024200015A1
Authority
WO
WIPO (PCT)
Prior art keywords
granulation
liquid
granulate
granules
inorganic filler
Prior art date
Application number
PCT/EP2024/056746
Other languages
English (en)
Inventor
Thomas Rupp
Original Assignee
Evonik Operations Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Operations Gmbh filed Critical Evonik Operations Gmbh
Publication of WO2024200015A1 publication Critical patent/WO2024200015A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • Process for the production of a granulate comprising the steps of a) preparing a granulation liquid, comprising the steps i) submitting a liquid comprising a binder, ii) adding an organic filler or inorganic filler to the liquid comprising a binder, iii) obtaining a granulation liquid, and b) preparing a granulation base by i) mixing of an inorganic filler selected form a weight increaser, inorganic salt and an inorganic buffer material, a carrier material, a disintegrant, an inorganic filler, and anticaking enhancer, in particular dry mixing, and obtaining the granulation base, and c) preparing the granulation composition by i) contacting, in particular spraying or pouring, of the granulation liquid with the granulation base and obtaining a granulation mixture comprising a liquid, and followed by d) sieving and/or extruding of the wet granulation mixture comprising liquid, and e) subjecting
  • the compounds can be in the form of pellets or granules, or extrudates with sufficient hardness properties, wherein each pellet, granule or extrudate may be coated for a retardation or sustain release as colon targeting.
  • a matrix particle in each described form can be used as well.
  • a typical MUPS tablet comprises multiple compressed functional particles, here compounds in form of a pellet, granule or extrudate. The particles can be compressed in a mixture with powdery excipients, such as disintegrants, fillers etc.
  • the pellets comprising an API active pharmaceutical ingredient
  • the tablet releases in the stomach into the individual pellets by the digestive secretion.
  • a particular advantage of coated pellets in contrast to coated conventional tablet formulations, is, that there is no immediate release of the entire active ingredient after a possible damage to the coating. Consequently, the risk of toxic effects due to overdose is avoided. Due to the different coating options of the individual pellets and their mixture, it is possible to process functional particles of different release kinetics in one dosage form. Further advantage of MUPS formulation is the shorter time frame, multiple small units can reach the section of action or resorption in gastric intestinal tract. Due to the MUPS formulation is disintegrating after swallowing in the stomach and release in multiple small functional units the passage in every fat stage is faster, compared with a single unit like a tablet.
  • WO 2010/031866A1 discloses a pellet composition and a process for their production.
  • the pellet formulation comprises aqueous lactose as granulation liquid sprayed on HPMC-particle and lactose.
  • the weight relation of lactose and HPMC is 50 : 50 or 40 : 60.
  • the obtained pellets have a particle size of 10 mm up to 25 mm.
  • the granulate is obtained to form the granulation composition after drying without further treatment.
  • the patent application further discusses the flowability, tamped density and bulk density.
  • US 6,770,368 B2 discloses spherical granules consisting of spray dried lactose and granular starch with a ratio of 90 to 10 and 25 to 75.
  • the friability is of less or equal to 80 % according to the mentioned test A in the patent.
  • a MUPS tablet comprises multiple pellets of different composition. Due to their good flowability it is difficult to obtain and maintain a homogenic pellet composition during storage, mixing and during compression of the composition into tablets. Therefore, there is a need for pellets, granules or extrudates that can increase the maintenance of homogeneity after blending/mixing, in process storage time frame and during compression or compaction by avoiding segregation. Furthermore, a composition and a process for the production of a granulate comprising pellets are needed that can either stabilise mechanically and/or chemically a homogenic blend after mixing.
  • Subject of the invention is therefore a process for the production of a granulate, in particular comprising excipients, more preferred placebo granulate, comprising the steps a) preparing a granulation liquid, comprising the steps i) submitting a liquid comprising a binder, ii) adding an organic filler or inorganic filler, preferred is an organic filler, in particular lactose and/or potato starch, to the liquid comprising a binder iii) obtaining a granulation liquid, b) preparing a granulation base comprising the steps i) mixing of an inorganic filler selected form a weight increaser, inorganic salt and an inorganic buffer material, in particular pentacalciumhydroxyd-tris(orthophosphate) or calcium sulfate, a carrier material, a disintegrant, an inorganic filler, selected from metal-oxide and/or half-metal oxide, and
  • the granulation liquid can be an aqueous suspension, dispersion or a solution.
  • the binder of the granulation liquid can comprise maize starch as an excipient.
  • An organic filler can comprise lactose, in particular lactose monohydrate and anhydrous lactose, potato starch or corn starch, an inorganic filler, in particular calcium hydrogen sulphate, as excipients or a mixture comprising at least one or at least two of the aforementioned excipients.
  • a preferred a) granulation liquid can comprise, in particular as excipients, 2 to 15 wt.-% binder, in particular maize starch, and 2 to 15 wt.-% of at least one organic filler, in particular comprising lactose, potato starch, or an inorganic filler, in particular calcium hydrogen sulphate, or a mixture comprising at least one ortwo of the aforementioned excipients, and a liquid, wherein the granulation liquid amounts to 100 wt.-%, and wherein the b) granulation base can comprise, in particular as excipients, 20 to 40 wt.-% inorganic filler selected form a weight increaser, inorganic salt and an inorganic buffer material, preferred pentacalciumhydroxyd-tris(orthophosphate) synonym to pentaCalcium hydroxide triphosphate or calcium sulfate, and 35 to 55 wt.-% carrier material, in particular microcrystalline cellulose, 5 to 20 wt.-
  • the inorganic salt comprises in particular an inorganic cation and an inorganic anion.
  • a preferred inorganic filler selected from a weight increaser, inorganic salt and buffer material is pentacalciumhydroxyd-tris(orthophosphate) or calcium sulfate, inorganic phosphate buffer and/or carbon dioxide silicate buffer.
  • carrier material microcrystalline cellulose can be used and as disintegrant or disintegration material maize starch can be used.
  • the inorganic filler can be selected from metal-oxide and/or half-metal oxide such as silicates, quartz, silicon dioxide, colloidal silicon dioxide and/or magnesium oxide. Preferred is Aerosil® 200.
  • microcrystalline cellulose can be used as well as other cellulose materials such as cellulose derivates whose hydroxyl groups are independently of one another at least partially alkylated, hydroxyalkylated, sulfonated, carboxyalkylated or/and xanthogenated.
  • the carrier material may comprise at least one cellulose derivative that is selected from the group consisting of hypromellose (HPMC), hypromellose phthalate, hydroxypropyl cellulose (HPC), hydroxyethyl cellulose, ethyl cellulose (EC), carboxymethyl cellulose (CMC), carboxyethyl cellulose (CEC) or/and sodium or/and calcium salts thereof.
  • the granulation composition may further comprise additional excipients that are selected from the group consisting of lubricants, fillers, binders, glidants, flow regulation agents, antistatic agents, solubilizers and humectants.
  • inorganic filler is different form the inorganic filler or fillers b) i).
  • the process may comprise the step, wherein the granulation liquid is sprayed or poured onto the granulation base, in particular the granulation liquid is sprayed or poured onto the granulation base in a mixing device, in particular in a rotating mixing device comprising a blade, more preferred a shovel, wherein the i) mixing device comprises a mixing tool, chopper, mixing housing and a cap for the housing, wherein the mixing tool has a rotor shaft that is guided through the cap or preferably through the bottom, wherein the mixing tool further has at least one mixing arm extending, in particular perpendicular, from the rotor shaft, wherein the arm has at its outer part a blade, in particular a shovel, in particular wherein the blade, in particular shovel, is directed upwards or ii) the mixing device comprises a mixing housing and a cap for the housing and a mixing tool, wherein the mixing tool has a rotor shaft extending through the bottom of the housing, wherein the mixing tool has at least one mixing arm extending
  • the granulation is preferred performed with a sieve insert, that provides at the inner side of the insert a lager cross-section of the opening than the cross-section of the opening at the outer side.
  • the cross-section of the opening at the inner side of the insert is particularly 10 % lager than the crosssection at the outer side, more preferred 15 % larger.
  • step d) may comprise the step of wet-sieving granulation of the granulation mixture comprising liquid, wherein the wet-sieving granulation can be performed with a sieve insert comprising a perforated insert, perforated plate, perforated conus, wherein the sieve insert has an inner side and an outer side, wherein the perforation of the outer-side is not identical to the perforation of the inner side.
  • the perforation of the insert comprises a triangular, semi-elliptical or triangular to semi-elliptical perforation, in particular the insert perforation which has a slanted and/or conical opening in the direction of the passage.
  • a sieve insert may be selected from CONIDUR®. Not preferred sieve inserts comprise round perforation with identical inner and outer side of the perforation of the sieve insert.
  • the mesh size or hole cross section is from 0.8 to 3mm.
  • Preferred granules are obtainable by sieving the granulation mixture comprising liquid through the sieve insert with a habitus comprising cylindric granules, bar-shaped granules and/or biscuit crumbs shape.
  • the rotor speed of the wet-sieving granulation device as well as the feeding speed of the granulation mixture comprising liquid may be adapted to the envisaged particle habitus and the particular sieve insert.
  • the process may comprise a drying step e) comprising the step of fluidized bed drying or infrared drying, in particular batchwise drying or continuously drying.
  • the drying may also be performed in a cyclone mixing system, for example from the company Huttlin.
  • the drying step is performed in more than one step, in particular the drying is performed in a cascade control, to avoid reducing or changing the particle form and/or size.
  • the granulate of the invention may be compound, in particular in form of a snatchy surfaced pellet, more preferred in form of a biscuit crumb.
  • the production steps of the granule preparation according to the present invention are suitable for easy scaling up, if this product would be implemented for big amounts.
  • Subject of the invention is also a granulate, preferred comprising the following excipients: 3 to 15 wt.- % binder, in particular maize starch
  • organic filler in particular comprising lactose or potato starch, or an inorganic filler, in particular calcium hydrogen sulphate, 20 to 70 wt.-% inorganic filler selected form a weight increaser, inorganic salt and an inorganic buffer material, in particular penta-calciumhydroxyd- tris(orthophosphate) or calcium sulfate as weight increaser, and optional 30 to 70 wt.-% carrier material, in particular microcrystalline cellulose, and optional 5 to 25 wt.-% disintegration material, in particular maize starch, and optional 1 to 10 wt.-% inorganic filler selected from metal-oxide and/or half-metal oxide, in particular silicon dioxide, preferred silicon dioxide with a particle size of 10 nm to 100 nm, more preferred silanised silicon dioxide particles, wherein the composition of the granule composition amounts to 100 wt.-%.
  • a preferred granulate, more preferably final granulate can comprise granules with at least two different diameters, in particular with three different diameters.
  • the diameter a) may be from 500 pm to 800 pm
  • the diameter b) may be from 1000 pm to 1300 pm
  • optionally the diameter c) may range from 1500 pm to 2000 pm, wherein all diameters are perpendicular to all other diameters.
  • the granulate may further comprise granules having a habitus of elliptical granules, bar-shaped granules and/or bicuspid granules. Particularly preferred is a granulate comprising surface modified granules. Wherein it is particularly preferred is the surface of the granules is coated with at least one polymer, in particular with a polymer comprising HO-, N-, NH-, CO- and/or COO-groups, or modified with at least one surfactant or at least one further polymer capable of polycondensation and/or polymerisation.
  • the polymer may comprise olefinic cellulose derivates, methacrylic and/or acrylic derivates.
  • the surface polymer comprising
  • HO-, N-, NH-, CO- and/or COO-groups of the granules can bond to other HO-, N-, NH-, CO- and/or COO-groups of polymers on neighbouring granules forming strong hydrogen bridges in a preferred supramolecular network which stabilises the obtained position of the particular granules in a homogeneous granulate composition. Therefore, the homogeneity of a composition can be chemically stabilized by a surface coating of the granules with polymers being able to form hydrogen bonds with polymers being a surface coating on neighbouring granules in a composition.
  • a dry sieving may be performed for a selection of the particle sizes.
  • a preferred sieve comprises a horizontal rotating or oscillating sieve, in particular a pressure sieve or screen.
  • the surface of the granules having a rough surface remains after the drying process, which can be seen form Fig. 1 .
  • subject of the invention may also be a granulate comprising, in particular the following excipients: 5 to 10 wt.-% binder, in particular maize starch, 5 to 10 wt.-% organic filler, in particular comprising lactose or potato starch or an inorganic filler, in particular calcium hydrogen sulphate, 20 to 50 wt.-% inorganic filler selected from a weight increaser, inorganic salt and an inorganic buffer material, in particular pentacalciumhydroxyd-tris(orthophosphate) or calcium sulfate as weight increaser, and optional 30 to 50 wt.-% carrier material, in particular microcrystalline cellulose, and optional 5 to 20 wt.-% disintegration material, in particular maize starch, and optional 1 to 10 wt.-% inorganic filler selected from metal-oxide and/or half-metal oxide, in particular silicon dioxide, preferred silicon dioxide with a particle size of 10 nm to 100 nm, more preferred silan
  • a granulate obtainable according to the process or granules is claimed, wherein the granules are used as a tabletting excipient compound, in particular as direct tabletting excipient compound, preferably in between other universal application for fast disintegrating and/or oral dispersing dosages, application of waxy and oily substrates and controlled release formulation or matrix formulation, more preferred in pharmaceutical compositions, food compositions, beverage compositions, supplements composition, hygienic compositions, dental cleaning or pool compositions as tabletting compound.
  • kits comprising the granules obtainable according to process of the invention or granules of the invention in a container is claimed, wherein the container comprises a measuring element enabling dosage of a predefined amount of the granules from the container.
  • Huttlin Mixing-Granulation or Glatt System comprising a mixing device, comprising a mixing housing and a cap for the housing, wherein the mixing tool has a rotor shaft that is guided through the cap or bottom, wherein the mixing tool further has at least one mixing arm extending perpendicular from the rotor shaft, wherein the arm has at its outer part a shovel, wherein shovel is directed upwards.
  • a chopper is installed preferably through the wall of the mixing housing.
  • mixing device comprises a mixing housing and a cap for the housing and a mixing tool, wherein the mixing tool has a rotor shaft at the bottom of the housing, wherein the tool has three mixing arms extending perpendicular from the rotor shaft, wherein the arm being a shovel, that is at one of its rotating long edges directed upwards.
  • a chopper is installed preferably through the wall of the mixing housing.
  • composition of granules for fast disintegrating tablet is a composition of granules for fast disintegrating tablet
  • microcrystalline cellulose 46.16 wt.-% microcrystalline cellulose as carrier material
  • Aerosil 200 1 .74 wt.-% Aerosil 200
  • a liquid comprising 10 wt.-% maize starch in water was prepared (C* PharmaGel 03406, 10 % aqueous).
  • a filler comprising lactose or potato starch was added.
  • the resulting granulation liquid comprises 10.0 wt.-% maize starch, 8.0 wt.-% of potato starch or lactose and water ad 100 wt.-% of the composition of the granulation liquid.
  • starch In the case of maize starch a pre-gelatinized version of the starch type can be used.
  • the granulation base contains 29.61 wt.-% pentacalciumhydroxydtris(orthophosphate) or calcium sulfate as weight increaser and 46.16 wt.-% microcrystalline cellulose in parts of Avicel PH 105 and PH 102 as carrier material, 10.97 wt.-% maize starch as disintegration/filler material, and 1 .73 wt.-% Aerosil 200.
  • Granulation liquid and granulation base were mixed 1 : 1 by weight.
  • composition of granules for oral dispersible tablet 6.27 wt.-% maize starch
  • microcrystalline cellulose 45.13 wt.-% microcrystalline cellulose as carrier material
  • a liquid comprising 10 wt.-% maize starch in water was prepared (C* PharmaGel 03406, 10 % aqueous).
  • a filler comprising lactose or potato starch was added to this liquid.
  • the resulting granulation liquid comprises 10.0 wt.-% maize starch, 8.0 wt.-% of potato starch or lactose and water ad 100 wt.-% of the composition of the granulation liquid.
  • a pre-gelatinized version of the starch type can be used.
  • the granulation base contains 28.93 wt.-% pentacalciumhydroxydtris(orthophosphate) or calcium sulfate as weight increaser and 45.13 wt.-% microcrystalline cellulose of Avicel PH 105 as carrier material, 10.72 wt.-% maize starch as disintegration/filler material, and 3.95 wt.-% Aerosil 200
  • Granulation liquid and granulation base are mixed 1 : 1 by weight.
  • composition of granules for matrix tablet formulation direct compressible
  • composition of granules for fast disintegrating tablet 6.12 wt.-% Glidant talc
  • the polymer application can be increased/decreased depending on the solubility of the API and/or the retardation time frame.
  • Caffeine was chosen because it is a micronized powder with a high solubility in acid and buffers to indicate one of the worst cases.
  • the competitor products for comparison trials were:
  • the compression force differs from product to product in between 12-25 KN to achieve a proper hardness.
  • the punch size is 10 mm
  • the resulting tablet height with the different products differs in comparison of the products depending on the product supplier and necessary compression force 0.2-0.5 mm
  • Texture Analyzer This Equipment was chosen in comparison to a disintegration tester. The Texture Analyzer provides more reliable data to compare fast disintegrating tablets.
  • results are documented with a decomposition diagram and video documentation for visual comparison of the test candidates.
  • Combilac of the company Meggle (patented in EP1175899 B1) Disintegrates as quickly as Example 1 granules in a 60ml warm water but has a strong tendency to attach to the punches and would therefore be unsuitable for production without modification. So, no "ready to use” tablet granules. Furthermore, this mixture flows poorly in the tablet press and thus causes weight deviations. The tablets accumulate in the tablet ramp of the tablet press due to poor slipping properties.
  • Example 1 granule provides a fast-disintegrating tablet.
  • the flowability in tablet press is steady.
  • the granule is easy compressible with low compression forces.
  • the example 1 granules can be used ready out of the box at future customers.
  • Example 2 granule provides a fast-disintegrating tablet in between 10 sec., which is suitable for ODT formulation.
  • the flowability in tablet press is steady by adding 0.5% Mg-stearate.
  • the granule is easy compressible with low compression forces.
  • the product was compressed on a single punch tablet compression equipment (Korsch XP1)
  • the punch size is 10mm
  • Example 3 granule is a further evolution of Example 1 granules by an additional process step whereon the granules are processed with a sustained release polymer for achieving a matrix granule which can be used for matrix tablets only by adding an arbitrary API.
  • the granule contains 15% functional polymer on granule weight.
  • Caffeine as model substance with 50% caffeine content in the final dosage form. This led to 7.5% polymer content in the final dosage form.
  • This tablet granule/caffeine blend is easy to compress with low compression forces. In this way of formulating a matrix tablet there isn’t needed to tread the API with a functional polymer first, potentially with the tablet mass, before it is formulated in a matrix system. This system conserves possible sensitive API against water or organic liquid impacts.
  • the product was compressed on a single punch tablet compression equipment (Korsch XP1) The compression velocity was adjusted for 10.000 tablets/h
  • the punch size is 10mm
  • Example 1 The granules of Example 1 are blended with AvailOM in 1 :1 weight ratio. This is compressed on a single punch tablet press.
  • the tablets don’t show significant oily surfaces.
  • the blend is easy to compress with low compression force.
  • Figure 1 Picture of granules after drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

Procédé de production d'un granulat, comprenant les étapes de a) préparation d'un liquide de granulation, comprenant les étapes i) soumission d'un liquide comprenant un liant, ii) ajout d'une charge organique ou d'une charge inorganique au liquide comprenant un liant, iii) obtention d'un liquide de granulation, et b) préparation d'une base de granulation par i) mélange d'une charge inorganique choisie parmi un agent d'augmentation de poids, un sel inorganique et un matériau tampon inorganique, un matériau de support, un délitant, une charge inorganique et un activateur anti-agglomérant, et obtention de la base de granulation, et c) préparation de la composition de granulation par i) mise en contact du liquide de granulation avec la base de granulation et obtention d'un mélange de granulation comprenant un liquide, puis d) tamisage et/ou extrusion du mélange de granulation humide comprenant du liquide, et e) soumission du mélange de granulation comprenant un liquide à un procédé de séchage et obtention de la composition de granulation. En outre, le granulat obtenu et un granulat ainsi que l'utilisation et un kit comprenant le granulat sont revendiqués.
PCT/EP2024/056746 2023-03-28 2024-03-14 Procédé de production d'un granulat et un granulat, en particulier un composé granulé d'excipients WO2024200015A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23164619 2023-03-28
EP23164619.1 2023-03-28

Publications (1)

Publication Number Publication Date
WO2024200015A1 true WO2024200015A1 (fr) 2024-10-03

Family

ID=85778893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/056746 WO2024200015A1 (fr) 2023-03-28 2024-03-14 Procédé de production d'un granulat et un granulat, en particulier un composé granulé d'excipients

Country Status (1)

Country Link
WO (1) WO2024200015A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770368B2 (en) 2000-07-27 2004-08-03 Roquette Freres Granules based on starch and lactose
US20070183955A1 (en) * 2003-07-16 2007-08-09 John Godber Hydroxyapaltite calcium phosphate granules, method for preparing same and uses thereof
US20100055179A1 (en) * 2006-12-21 2010-03-04 Mallinckrodt Inc. Composition of and Method for Preparing Orally Disintegrating Tablets Containing a High Dose of Pharmaceutically Active Ingredients
WO2010031866A1 (fr) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co.Kg Auxiliaire de pastillage à base de lactose et de cellulose
CN102670536A (zh) * 2012-06-08 2012-09-19 上海新亚药业有限公司 头孢克肟分散片的制备方法
CN102935110A (zh) * 2012-11-02 2013-02-20 青岛康地恩药业股份有限公司 一种含天然牛至香酚的禽用包被颗粒剂及其制备方法
WO2022172076A1 (fr) * 2021-02-09 2022-08-18 DWIVEDI, Dr. Jayesh Préparation d'un nouvel excipient cotraité séché par micro-ondes de saccharose et formulation de comprimé de comprimés de canagliflozine utilisant l'excipient cotraité

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770368B2 (en) 2000-07-27 2004-08-03 Roquette Freres Granules based on starch and lactose
EP1175899B1 (fr) 2000-07-27 2007-08-29 Roquette FrÀ¨res Granules à base d'amidon et de lactose
US20070183955A1 (en) * 2003-07-16 2007-08-09 John Godber Hydroxyapaltite calcium phosphate granules, method for preparing same and uses thereof
US20100055179A1 (en) * 2006-12-21 2010-03-04 Mallinckrodt Inc. Composition of and Method for Preparing Orally Disintegrating Tablets Containing a High Dose of Pharmaceutically Active Ingredients
WO2010031866A1 (fr) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co.Kg Auxiliaire de pastillage à base de lactose et de cellulose
CN102670536A (zh) * 2012-06-08 2012-09-19 上海新亚药业有限公司 头孢克肟分散片的制备方法
CN102935110A (zh) * 2012-11-02 2013-02-20 青岛康地恩药业股份有限公司 一种含天然牛至香酚的禽用包被颗粒剂及其制备方法
WO2022172076A1 (fr) * 2021-02-09 2022-08-18 DWIVEDI, Dr. Jayesh Préparation d'un nouvel excipient cotraité séché par micro-ondes de saccharose et formulation de comprimé de comprimés de canagliflozine utilisant l'excipient cotraité

Similar Documents

Publication Publication Date Title
JP5718231B2 (ja) エリスリトールの打錠
AU785135B2 (en) Granules based on starch and lactose
US5104648A (en) High ibuprofen content granulations
US9655851B2 (en) Granular material for dosage forms
JP5714600B2 (ja) 共加工された錠用賦形剤混合物、その調製及び使用
JPS62174013A (ja) 直打用ビタミン顆粒、その製造法および錠剤
CA2045680C (fr) Granules ayant une forte teneur en ibuprofene
JP5753081B2 (ja) 口腔内崩壊性マンニトール
US8663684B2 (en) Lactose and cellulose-based tableting aid
JPH0753663B2 (ja) チアミン塩の顆粒，その製造法および錠剤
KR20070104257A (ko) 장용성 고체 분산체를 포함하는 고형 제제
JP2001502667A (ja) 直接圧縮可能なラクチトールおよび方法
Cantor et al. Pharmaceutical granulation processes, mechanism, and the use of binders
US10391072B2 (en) High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
JP6630229B2 (ja) レベチラセタム含有医薬組成物及びその製造方法
JPH05320045A (ja) 錠剤に直接圧縮可能な医薬粉末組成物を製造するための噴霧乾燥法
WO1997033571A1 (fr) Preparation d'ecadotril a microdispersion et liberation rapides
WO2024200015A1 (fr) Procédé de production d'un granulat et un granulat, en particulier un composé granulé d'excipients
WO2020004393A1 (fr) Procédé de traitement pour particules de médicament brut de taille de particule non uniforme
EP1738750A1 (fr) Méthode pour granulation de carbonate du calcium et des produits resultants
US9629809B2 (en) High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
JP2007182411A (ja) ポリカルボフィルカルシウム含有粒剤
CZ2016573A3 (cs) Pevná formulace abirateronu acetátu vyráběná technologií fluidní granulace
EP4321154A1 (fr) Comprimé de tolvaptan et au moins un liant traité par granulation par pulvérisation
CA2894272A1 (fr) Granules d'ibuprofene sodique a teneur elevee, leur preparation et leur utilisation dans la preparation de formes posologiques solides non effervescentes